Leki przeciwdepresyjne (Polish Wikipedia)

Analysis of information sources in references of the Wikipedia article "Leki przeciwdepresyjne" in Polish language version.

refsWebsite
Global rank Polish rank
2nd place
6th place
4th place
7th place
5th place
2nd place
1st place
1st place
low place
585th place
3,844th place
222nd place
268th place
403rd place
low place
low place
4,294th place
205th place
low place
4,822nd place
low place
3,352nd place
120th place
180th place
1,785th place
3,736th place
low place
low place
low place
low place
low place
low place
719th place
1,030th place
low place
4,810th place
low place
low place

aljazeera.com

america.aljazeera.com

beyondmeds.com

doi.org

dx.doi.org

  • Pharmaceutical consumption, [w:] Health at a Glance 2013. OECD Indicators, OECD Publishing, 2013, s. 102-103, DOI10.1787/health_glance-2013-41-en, ISBN 978-92-64-20502-4 (ang.).
  • R.C. Heel i inni, Zimelidine: a review of its pharmacological properties and therapeutic efficacy in depressive illness, „Drugs”, 24 (3), 1982, s. 169–206, DOI10.2165/00003495-198224030-00001, PMID6215240 [dostęp 2021-04-21] (ang.).
  • Jakob Solgaard Jensen, Andreas Ørsted Bielefeldt, Asbjørn Hróbjartsson, Active placebo control groups of pharmacological interventions were rarely used but merited serious consideration: a methodological overview, „Journal of Clinical Epidemiology”, 87, 2017, s. 35–46, DOI10.1016/j.jclinepi.2017.03.001, PMID28342907 [dostęp 2021-04-21] (ang.).
  • Irving Kirsch, Antidepressants and the Placebo Effect, „Zeitschrift für Psychologie”, 222 (3), 2014, s. 128–134, DOI10.1027/2151-2604/a000176, PMID25279271, PMCIDPMC4172306 [dostęp 2021-04-21] (ang.).
  • Irving Kirsch, Challenging Received Wisdom: Antidepressants and the Placebo Effect, „McGill Journal of Medicine”, 11 (2), 2008, s. 219–222, DOI10.26443/mjm.v11i2.571, PMID19148327, PMCIDPMC2582668 [dostęp 2021-04-21] (ang.).
  • J.G. Rabkin i inni, How blind is blind? Assessment of patient and doctor medication guesses in a placebo-controlled trial of imipramine and phenelzine, „Psychiatry Research”, 19 (1), 1986, s. 75–86, DOI10.1016/0165-1781(86)90094-6, PMID3538107 [dostęp 2021-04-21] (ang.).
  • I. Kirsch, G. Sapirstein, Listening to Prozac but hearing placebo: A meta-analysis of antidepressant medication, „Prevention & Treatment”, DOI10.1037/1522-3736.1.1.12a (ang.).
  • Corrado Barbui i inni, Efficacy of antidepressants and benzodiazepines in minor depression: systematic review and meta-analysis, „British Journal of Psychiatry”, 198 (1), 2011, s. 11–16, DOI10.1192/bjp.bp.109.076448, PMID21200071, PMCIDPMC3014462 [dostęp 2021-04-21] (ang.).
  • Hypericum Depression Trial Study Group, Effect of Hypericum perforatum (St John's wort) in major depressive disorder: a randomized controlled trial, „Journal of the American Medical Association”, 287 (14), 2002, s. 1807–1814, DOI10.1001/jama.287.14.1807, PMID11939866 [dostęp 2021-04-21] (ang.).
  • Joanna Moncrieff, The myth of the chemical cure: a critique of psychiatric drug treatment, Basingstoke: Palgrave Macmillan, 2008, s. 217-224, DOI10.1007/978-0-230-58944-5, ISBN 978-0-230-58944-5, OCLC 300481932 (ang.).
  • J. Moncrieff, S. Wessely, R. Hardy, Active placebos versus antidepressants for depression, „The Cochrane Database of Systematic Reviews” (1), 2004, art. nr CD003012, DOI10.1002/14651858.CD003012.pub2, PMID14974002 [dostęp 2021-04-21] (ang.).
  • O. Benkert i inni, Dose escalation vs. continued doses of paroxetine and maprotiline: a prospective study in depressed out-patients with inadequate treatment response, „Acta Psychiatrica Scandinavica”, 95 (4), 1997, s. 288–296, DOI10.1111/j.1600-0447.1997.tb09634.x, PMID9150822 [dostęp 2021-04-21] (ang.).
  • Stuart A. Montgomery, Antidepressant or antidepressant plus placebo effect?, „World Psychiatry”, 14 (3), 2015, s. 303–304, DOI10.1002/wps.20244, PMID26407781, PMCIDPMC4592648 [dostęp 2021-04-21] (ang.).
  • Wojciech Oronowicz, Antydepresanty a efekt placebo, 2017, DOI10.13140/RG.2.2.25818.13765 [dostęp 2021-04-21].
  • P. Bollini i inni, Effectiveness of antidepressants. Meta-analysis of dose-effect relationships in randomised clinical trials, „The British Journal of Psychiatry: The Journal of Mental Science”, 174, 1999, s. 297–303, DOI10.1192/bjp.174.4.297, PMID10533547 [dostęp 2021-04-21] (ang.).
  • Giovanni A. Fava i inni, Effects of gradual discontinuation of selective serotonin reuptake inhibitors in panic disorder with agoraphobia, „The International Journal of Neuropsychopharmacology”, 10 (6), 2007, s. 835–838, DOI10.1017/S1461145706007462, PMID17224089 [dostęp 2021-04-21] (ang.).
  • Alessandro Serretti, Alberto Chiesa, Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis, „Journal of Clinical Psychopharmacology”, 29 (3), 2009, s. 259–266, DOI10.1097/JCP.0b013e3181a5233f, PMID19440080 [dostęp 2021-04-21] (ang.).
  • Joseph F. Goldberg, Christine J. Truman, Antidepressant-induced mania: an overview of current controversies, „Bipolar Disorders”, 5 (6), 2003, s. 407–420, DOI10.1046/j.1399-5618.2003.00067.x, PMID14636364 [dostęp 2021-04-21] (ang.).
  • F. Benazzi, Antidepressant-associated hypomania in outpatient depression: a 203-case study in private practice, „Journal of Affective Disorders”, 46 (1), 1997, s. 73–77, DOI10.1016/s0165-0327(97)00082-7, PMID9387089 [dostęp 2021-04-21] (ang.).
  • Jerzy A. Sobański i inni, Czy cechy osobowości i nasilenie objawów nerwicowych wiążą się ze sprawozdawaniem myśli samobójczych u pacjentów dziennego oddziału leczenia zaburzeń nerwicowych?, „Psychiatria Polska”, 49 (6), 2015, s. 1343–1358, DOI10.12740/psychiatriapolska.pl/online-first/5 [dostęp 2021-04-21].
  • Robert D. Gibbons i inni, Suicidal thoughts and behavior with antidepressant treatment: reanalysis of the randomized placebo-controlled studies of fluoxetine and venlafaxine, „Archives of General Psychiatry”, 69 (6), 2012, s. 580–587, DOI10.1001/archgenpsychiatry.2011.2048, PMID22309973, PMCIDPMC3367101 [dostęp 2021-04-21] (ang.).
  • Keith Hawton, Kate E.A. Saunders, Rory C. O'Connor, Self-harm and suicide in adolescents, „The Lancet”, 379 (9834), 2012, s. 2373–2382, DOI10.1016/S0140-6736(12)60322-5, PMID22726518 [dostęp 2021-04-21].
  • Sarah E. Hetrick i inni, Newer generation antidepressants for depressive disorders in children and adolescents, „The Cochrane Database of Systematic Reviews”, 11, 2012, art. nr CD004851, DOI10.1002/14651858.CD004851.pub3, PMID23152227 [dostęp 2021-04-21] (ang.).
  • Felice N. Jacka i inni, Association between magnesium intake and depression and anxiety in community-dwelling adults: the Hordaland Health Study, „The Australian and New Zealand Journal of Psychiatry”, 43 (1), 2009, s. 45–52, DOI10.1080/00048670802534408, PMID19085527 [dostęp 2021-04-21] (ang.).
  • Mihai Nechifor, Magnesium in major depression, „Magnesium Research”, 22 (3), 2009, 163S–166S, DOI10.1684/mrh.2009.0177, PMID19780403 [dostęp 2021-04-21] (ang.).

doi.org

drugbank.ca

ipin.edu.pl

ppn.ipin.edu.pl

medscape.com

nih.gov

ncbi.nlm.nih.gov

  • R.C. Heel i inni, Zimelidine: a review of its pharmacological properties and therapeutic efficacy in depressive illness, „Drugs”, 24 (3), 1982, s. 169–206, DOI10.2165/00003495-198224030-00001, PMID6215240 [dostęp 2021-04-21] (ang.).
  • Jakob Solgaard Jensen, Andreas Ørsted Bielefeldt, Asbjørn Hróbjartsson, Active placebo control groups of pharmacological interventions were rarely used but merited serious consideration: a methodological overview, „Journal of Clinical Epidemiology”, 87, 2017, s. 35–46, DOI10.1016/j.jclinepi.2017.03.001, PMID28342907 [dostęp 2021-04-21] (ang.).
  • Irving Kirsch, Antidepressants and the Placebo Effect, „Zeitschrift für Psychologie”, 222 (3), 2014, s. 128–134, DOI10.1027/2151-2604/a000176, PMID25279271, PMCIDPMC4172306 [dostęp 2021-04-21] (ang.).
  • Irving Kirsch, Challenging Received Wisdom: Antidepressants and the Placebo Effect, „McGill Journal of Medicine”, 11 (2), 2008, s. 219–222, DOI10.26443/mjm.v11i2.571, PMID19148327, PMCIDPMC2582668 [dostęp 2021-04-21] (ang.).
  • J.G. Rabkin i inni, How blind is blind? Assessment of patient and doctor medication guesses in a placebo-controlled trial of imipramine and phenelzine, „Psychiatry Research”, 19 (1), 1986, s. 75–86, DOI10.1016/0165-1781(86)90094-6, PMID3538107 [dostęp 2021-04-21] (ang.).
  • Corrado Barbui i inni, Efficacy of antidepressants and benzodiazepines in minor depression: systematic review and meta-analysis, „British Journal of Psychiatry”, 198 (1), 2011, s. 11–16, DOI10.1192/bjp.bp.109.076448, PMID21200071, PMCIDPMC3014462 [dostęp 2021-04-21] (ang.).
  • Hypericum Depression Trial Study Group, Effect of Hypericum perforatum (St John's wort) in major depressive disorder: a randomized controlled trial, „Journal of the American Medical Association”, 287 (14), 2002, s. 1807–1814, DOI10.1001/jama.287.14.1807, PMID11939866 [dostęp 2021-04-21] (ang.).
  • J. Moncrieff, S. Wessely, R. Hardy, Active placebos versus antidepressants for depression, „The Cochrane Database of Systematic Reviews” (1), 2004, art. nr CD003012, DOI10.1002/14651858.CD003012.pub2, PMID14974002 [dostęp 2021-04-21] (ang.).
  • O. Benkert i inni, Dose escalation vs. continued doses of paroxetine and maprotiline: a prospective study in depressed out-patients with inadequate treatment response, „Acta Psychiatrica Scandinavica”, 95 (4), 1997, s. 288–296, DOI10.1111/j.1600-0447.1997.tb09634.x, PMID9150822 [dostęp 2021-04-21] (ang.).
  • Stuart A. Montgomery, Antidepressant or antidepressant plus placebo effect?, „World Psychiatry”, 14 (3), 2015, s. 303–304, DOI10.1002/wps.20244, PMID26407781, PMCIDPMC4592648 [dostęp 2021-04-21] (ang.).
  • Peter D Kramer i inni, The truth about Prozac: an exchange, „New York Review of Books”, 55 (2), 2008, s. 54–55, PMID18271121 [dostęp 2021-04-21] (ang.).
  • P. Bollini i inni, Effectiveness of antidepressants. Meta-analysis of dose-effect relationships in randomised clinical trials, „The British Journal of Psychiatry: The Journal of Mental Science”, 174, 1999, s. 297–303, DOI10.1192/bjp.174.4.297, PMID10533547 [dostęp 2021-04-21] (ang.).
  • Giovanni A. Fava i inni, Effects of gradual discontinuation of selective serotonin reuptake inhibitors in panic disorder with agoraphobia, „The International Journal of Neuropsychopharmacology”, 10 (6), 2007, s. 835–838, DOI10.1017/S1461145706007462, PMID17224089 [dostęp 2021-04-21] (ang.).
  • Alessandro Serretti, Alberto Chiesa, Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis, „Journal of Clinical Psychopharmacology”, 29 (3), 2009, s. 259–266, DOI10.1097/JCP.0b013e3181a5233f, PMID19440080 [dostęp 2021-04-21] (ang.).
  • S. Chebili i inni, [Antidepressants and sexual stimulation: the correlation], „L'Encephale”, 24 (3), 1998, s. 180–184, PMID9696909 [dostęp 2021-04-21] (fr.).
  • Joseph F. Goldberg, Christine J. Truman, Antidepressant-induced mania: an overview of current controversies, „Bipolar Disorders”, 5 (6), 2003, s. 407–420, DOI10.1046/j.1399-5618.2003.00067.x, PMID14636364 [dostęp 2021-04-21] (ang.).
  • F. Benazzi, Antidepressant-associated hypomania in outpatient depression: a 203-case study in private practice, „Journal of Affective Disorders”, 46 (1), 1997, s. 73–77, DOI10.1016/s0165-0327(97)00082-7, PMID9387089 [dostęp 2021-04-21] (ang.).
  • BI. Yerevanian, RJ. Koek, JD. Feusner, S. Hwang i inni. Antidepressants and suicidal behaviour in unipolar depression. „Acta Psychiatr Scand”. 110 (6), s. 452-458, 2004. DOI: 10.1111/j.1600-0447.2004.00437.x. PMID: 15521830. 
  • Robert D. Gibbons i inni, Suicidal thoughts and behavior with antidepressant treatment: reanalysis of the randomized placebo-controlled studies of fluoxetine and venlafaxine, „Archives of General Psychiatry”, 69 (6), 2012, s. 580–587, DOI10.1001/archgenpsychiatry.2011.2048, PMID22309973, PMCIDPMC3367101 [dostęp 2021-04-21] (ang.).
  • Keith Hawton, Kate E.A. Saunders, Rory C. O'Connor, Self-harm and suicide in adolescents, „The Lancet”, 379 (9834), 2012, s. 2373–2382, DOI10.1016/S0140-6736(12)60322-5, PMID22726518 [dostęp 2021-04-21].
  • Sarah E. Hetrick i inni, Newer generation antidepressants for depressive disorders in children and adolescents, „The Cochrane Database of Systematic Reviews”, 11, 2012, art. nr CD004851, DOI10.1002/14651858.CD004851.pub3, PMID23152227 [dostęp 2021-04-21] (ang.).
  • Ross J. Baldessarini, Leonardo Tondo, John Hennen, Lithium treatment and suicide risk in major affective disorders: update and new findings, „The Journal of Clinical Psychiatry”, 64 Suppl 5, 2003, s. 44–52, PMID12720484 [dostęp 2021-04-21] (ang.).
  • Felice N. Jacka i inni, Association between magnesium intake and depression and anxiety in community-dwelling adults: the Hordaland Health Study, „The Australian and New Zealand Journal of Psychiatry”, 43 (1), 2009, s. 45–52, DOI10.1080/00048670802534408, PMID19085527 [dostęp 2021-04-21] (ang.).
  • K. Wilson, V. Brakoulias. Magnesium intake and depression. „Aust N Z J Psychiatry”. 43 (6), s. 580, 2009. PMID: 19452662. 
  • Mihai Nechifor, Magnesium in major depression, „Magnesium Research”, 22 (3), 2009, 163S–166S, DOI10.1684/mrh.2009.0177, PMID19780403 [dostęp 2021-04-21] (ang.).

nybooks.com

pan.pl

instytucja.pan.pl

prc.krakow.pl

priory.com

przychodnia.pl

  • Bimanol, [w:] Encyklopedia leków [online], Przychodnia.pl [dostęp 2015-01-21] [zarchiwizowane z adresu 2007-12-20].

qualitywatch.org.uk

researchgate.net

silo.tips

survivingantidepressants.org

viamedica.pl

czasopisma.viamedica.pl

web.archive.org

  • Jerzy Wordliczek, Renata Zajączkowska, Jan Dobrogowski, Farmakologiczne leczenie bólu neuropatycznego, „Polski Przegląd Neurologiczny”, 1, 7, 2007, s. 39–48 [zarchiwizowane z adresu 2015-01-29].
  • Bimanol, [w:] Encyklopedia leków [online], Przychodnia.pl [dostęp 2015-01-21] [zarchiwizowane z adresu 2007-12-20].

worldcat.org